



## UNITED STATES PATENT AND TRADEMARK OFFICE



DATE MAILED: 11-14/2002

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO
09 883,093	06 14 2001	Catherine Guenther	R-126	7936
75	96 11 14 2002			
DELTAGEN, INC.			EXAMINER	
1003 Hamilton Avenue Menlo Park, CA 94025			WILSON, MICHAEL C	
			ART UNIT	PAPER NUMBER
			1632	Ti

Please find below and/or attached an Office communication concerning this application or proceeding.







## UNITED STATES ARE ENT OF COMMERCE Patent and Trademark Office

Address ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ CONTROL NO. FILING DATE

FIRST NAMED INVENTOR / PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER

ART UNIT PAPER

10

RECEIVED

DATE MAILED:

DEC 1 3 2002

TECH CENTER 1600/2900

Please find below and/or attached an Office communication concerning this application or proceeding.

## Commissioner of Patents and Trademarks

The reply filed on 11-7-02, paper number 9, is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): a marked up version of the figure has not been provided. In addition, it would be more efficient to get a draftsman's review of the drawings before amending Figure 2A. To comply with the Sequence rules as required in the office action sent 10-2-02, paper number 7, applicants should insert a sentence describing Figure 2A as containing SEQ ID NO:1 into the description of Figure 2A-2B on page 8, line 13. After "hormone receptor genes." insert a description of Fig. 2A, e.g. – Figure 2A shows.....(SEQ ID NO:1).--

See 37 CFR 1.111. Since the above mentioned reply appears to be *bona fide*, applicant is given **ONE** (1) **MONTH or THIRTY** (30) **DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).